BlackRock’s Immunocore IMCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$19.8M Buy
656,309
+327,210
+99% +$10.6M ﹤0.01% 3087
2025
Q4
$11.4M Buy
329,099
+83,894
+34% +$2.96M ﹤0.01% 3397
2025
Q3
$8.91M Buy
245,205
+23,826
+11% +$809K ﹤0.01% 3509
2025
Q2
$6.95M Sell
221,379
-4,166
-2% -$129K ﹤0.01% 3599
2025
Q1
$6.69M Sell
225,545
-47,235
-17% -$1.42M ﹤0.01% 3515
2024
Q4
$8.05M Sell
272,780
-600,831
-69% -$19M ﹤0.01% 3533
2024
Q3
$27.2M Buy
873,611
+1,818
+0.2% +$66.1K ﹤0.01% 2836
2024
Q2
$29.5M Buy
871,793
+4,436
+0.5% +$226K ﹤0.01% 2748
2024
Q1
$56.4M Buy
867,357
+88,326
+11% +$6.06M ﹤0.01% 2369
2023
Q4
$53.2M Buy
779,031
+19,198
+3% +$998K ﹤0.01% 2435
2023
Q3
$39.4M Sell
759,833
-32,251
-4% -$1.91M ﹤0.01% 2539
2023
Q2
$47.5M Buy
792,084
+14,158
+2% +$808K ﹤0.01% 2518
2023
Q1
$38.5M Sell
777,926
-11,069
-1% -$622K ﹤0.01% 2623
2022
Q4
$45M Buy
788,995
+289,563
+58% +$16.3M ﹤0.01% 2544
2022
Q3
$23.4M Buy
499,432
+3,250
+0.7% +$155K ﹤0.01% 2948
2022
Q2
$18.5M Hold
496,182
﹤0.01% 3128
2022
Q1
$14.8M Hold
496,182
﹤0.01% 3362
2021
Q4
$17M Sell
496,182
-331,422
-40% -$12M ﹤0.01% 3374
2021
Q3
$30.7M Sell
827,604
-252,322
-23% -$8.52M ﹤0.01% 3000
2021
Q2
$42.2M Sell
1,079,926
-199
-0% -$7.68K ﹤0.01% 2810
2021
Q1
$46M Buy
+1,080,125
New +$48.1M ﹤0.01% 2672

Other funds holding IMCR

BlackRock's IMCR Position: Q1 2026 in Review

BlackRock increased its Immunocore (IMCR) stake by 99% in Q1 2026, buying an estimated $10.6M and bringing the position to 656,309 shares worth $19.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3087.

BlackRock first reported a position in IMCR in Q1 2021 and has held it in 21 quarters since. The position peaked at $56.4M in Q1 2024. 142 funds tracked by Wall St. Rank hold IMCR as of Q1 2026.

  • BlackRock held 656,309 shares of Immunocore worth $19.8M as of Q1 2026.
  • BlackRock bought 327,210 Immunocore shares in Q1 2026, an estimated $10.6M.
  • Immunocore made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #3087 holding.
  • BlackRock first reported a position in Immunocore in Q1 2021 and has held it in 21 quarters since.
  • BlackRock's Immunocore position peaked at $56.4M in Q1 2024.
  • 142 funds tracked by Wall St. Rank held Immunocore as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.